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Purpose. To report the use of inﬂiximab in the rapid stabilization of a case of progressive, bilateral rheumatoid peripheral
ulcerative keratitis (PUK) that failed to respond to conventional immunosuppressive therapy. Methods. A single interventional
case report. Results. A patient with rheumatoid arthritis presented with bilateral PUK following a 2-month history of ocular
discomfortandredness.Hissystemicprednisolone(PDN)andmethotrexate(MTX)wereincreasedand,despiteaninitialfavorable
response, bilateral recurrent corneal perforations ensued. Both eyes underwent cyanoacrylate glue repair, amniotic membrane
transplantation (AMT), and penetrating keratoplasty (PKP). Recurrence of the disease and bilateral perforations of the second
PKPinbotheyespromptedadministrationofintravenousinﬂiximabimmediatelyafterthefourthPKP.Thediseaseactivityrapidly
settled in both eyes, and at eighteen-month followup, after 12 inﬂiximab infusions, the PUK remains quiescent with no further
graft thinning or perforation. Conclusion. Inﬂiximab can be used to arrest the progression of severe bilateral rheumatoid PUK in
cases that are refractory to conventional treatment.
1.Introduction
Peripheral ulcerative keratitis (PUK) is an uncommon
inﬂammatory condition that is associated with collagen
vascular diseases such as rheumatoid arthritis (RA) [1].
Conventional systemic immunosuppressive therapy may fail
and lead to relentlessly progressive disease with corneal
perforation and blindness. Intravenous inﬂiximab has been
reported to halt the progression of PUK in RA and in other
destructive inﬂammatory corneal conditions [2] including
Mooren’s ulcer [3]. We describe the use of inﬂiximab to sta-
bilize progressive and recurrent corneal melting in bilateral
tectonic penetrating keratoplasties for PUK associated with
RA. To the best of our knowledge, this would not appear to
have been reported before.
2.MaterialsandMethods
2.1. Case Report. A 47-year-old Sri Lankan male presented
in October 2006 with a 3-month history of bilateral red
watery eyes with a foreign body sensation. He had RA, which
was quiescent at presentation for which he was taking oral
diclofenac, prednisolone (PDN), and methotrexate (MTX)
with calcium and folic acid supplements.
On examination, his best corrected visual acuity (BCVA)
was 6/19 right eye (OD) and 6/9 left eye (OS). There was
an inferonasal peripheral crescent-shaped area of corneal
thinning (80%) forming a gutter from 3 to 6 o’clock, 1.4mm
wide in the right eye, while in the left eye there was a
smaller inferonasal gutter with 20% thinning. His PDN and
MTX were increased and hourly topical carmellose sodium
0.5%added.Initialreductionofoculardiscomfortprompted
reduction of his systemic medication, but on review within 9
days BCVA OD was reduced to 6/38 and the right anterior
chamber was shallow with a small corneal perforation noted
in the corneal gutter. This was plugged with iris and not
actively leaking. The perforation was repaired with corneal
cyanoacrylate glue and a bandage contact lens (BCL) was
placed for comfort and exchanged at 6 weekly intervals
thereafter. Slow tapering of his systemic medication was2 Case Reports in Ophthalmological Medicine
Figure 1: Bilateral inferonasal crescent-shaped corneal thinning with perforation and iris prolapse, June 2009.
Figure 2: Bilateral iris reconstruction and inferonasal tectonic keratoplasties, June 2009.
attempted again. On review 4 months later in February 2007,
a small leak from the previous perforation was noted. After
further cyanoacetate glue repair, he underwent multilayered
amniotic membrane graft (AMG) to the right eye in March
2007.
Initially his postoperative course was satisfactory but at-
tendance at follow-up appointments was poor. In June 2009,
heattendedwithmarkeddiscomfortandrednessofbotheyes
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with no signs of active RA. He was found to have marked
bilateral inferior corneal stromal thinning with perforations
in the inferotemporal mid-periphery and a small iris pro-
lapse plugging the hole in both eyes (Figure 1). Bilateral
emergency tectonic penetrating keratoplasties (PKP) were
performed, decentered infero-nasally in order to replace
the thinned cornea (Figure 2). Lamellar grafts were initially
attempted but was converted to a PKP as a satisfactory
lamellar plane was impossible to create due to a soft eye
from the perforations. His systemic medications were again
increased.
One week postoperatively, BCVA was 6/38 OD and 6/19
OSbutonemonthlaterhepresentedwithrecurrent,bilateral
paracentral corneal melts. Glue repair was again performed
and topical cyclosporine 0.5% twice daily was added to both
eyes. He subsequently underwent a further triple-layered
AMG and second PKP to both eyes in September 2009.
Inﬂiximab (5mg/kg intravenously) was commenced on
the ﬁrst postoperative day and he continued to receive cycles
at the same dose at weeks 2 and 6 and then every 8 weeks,
while PDN and MTX were gradually reduced. Since he was
from an area of high prevalence of tuberculosis, prophylactic
isoniazid was commenced. He underwent uncomplicated
phacoemulsiﬁcation with posterior chamber intraocular
implantation in both eyes in June 2010. Eighteen months
following inﬂiximab therapy both eyes remained quiet with
no signs of further corneal melting. The BCVA was 6/48 in
both eyes, limited by subepithelial haze and thinning of his
corneal grafts (Figure 3).
3. Discussion
Peripheral ulcerative keratitis is a rare corneal disease asso-
ciated with rheumatoid arthritis and is indicative of active
local vasculitis [1]. Deregulated proteolytic mechanisms
within the corneal stroma cause rapid corneal thinning and
perforation, which can be aggressive and recurrent. The
b i o c h e m i c a lp a t h w a y si n v o l v e da r en u m e r o u sa n dn o ty e t
fully understood.
Healthy corneal tissue contains proteinases, which are
upregulated and activated in the damaged cornea, their
synthesisbeingincreasedbyproinﬂammatorycytokinessuch
as tumour necrosis factor-alpha (TNFα) and interleukin-
1( I L - 1 )[ 4]. These proteinases are regulated by speciﬁc
inhibitors in healthy ocular surface tissues and tear ﬁlm, thus
preventing excessive degradation of healthy stroma. Unreg-
ulated matrix metalloproteinases (MMPs) are generated
through several inﬂammatory pathways and considered to
be largely responsible for the destruction of the extracellular
matrix. The increased expression and activity of a wide
range of MMPs, particularly MMP-9, a gelatinase which
degrades collagen [5], has been demonstrated in melted
human corneal samples [4] and in veterinary studies.
Deﬁciencies in the corneal surface environment, includ-
ing keratoconjunctivitis sicca, may initiate stromal lysis, thus
increasing the risk of recurrent melts and graft failure [5].Case Reports in Ophthalmological Medicine 3
Figure 3: Right and left eyes after repeated penetrating keratoplasty and cataract extraction with intraocular lens implant, September 2010.
In humans with dry eye symptoms, MMP-9, IL-1β,a n d
TNF-α expression and activity in conjunctival epithelial cells
are higher than in controls and correlate well with clinical
parameters [6]. Topical cyclosporine A has been established
as an eﬀective treatment for dry eye and was thus used in our
patient to dampen the local inﬂammatory response.
TNFα is a proinﬂammatory cytokine that is a major
mediator of inﬂammation, immunity, and apoptosis. It
increases vascular endothelial permeability, enhances leuco-
cytechemotaxisfrombloodvesselsintotissues,andincreases
expression of cellular adhesion molecules. In human corneal
epithelial cell cultures, TNFα stimulates MMP-9 activity in
a dose-dependent manner [4]. This is key evidence that
TNFα may contribute to the keratolytic pathway and could
therefore be an important therapeutic target in treating
corneal melts.
The keratolytic processes that cause corneal melting may
persist even after PKP and are a common cause of graft
failure. Graft survival is signiﬁcantly improved with systemic
immunosuppressionbutcornealmeltsmaystillrecurdespite
the use of diﬀerent agents. Individual variations in the
immune response are likely to play an important role in
clinical outcome.
The anti-TNFα agent inﬂiximab is a chimeric mono-
clonal antibody, which prevents free- and membrane-bound
TNFα binding to its cellular receptor and induces apoptosis
in activated T-cells expressing TNFα [7]. It reduces upreg-
ulation of TNFα at sites of inﬂammation. Administration
is by 8 weekly intravenous infusion after loading doses at
0, 2, and 6 weeks and in the UK requires supervision by a
rheumatologist. It is currently used systemically to treat RA,
ankylosing spondylitis, Crohn’s disease, and psoriasis. We
elected to use a higher dose (5mg/kg) of inﬂiximab rather
than the standard (3mg/kg) dose typically used for systemic
rheumatoid arthritis in view of the bilateral involvement and
advanced severity of corneal disease.
Another anti-TNFα agent, etanercept, has been reported
totreatsterilecornealulcerationininﬂammatorydiseasebut
current data is insuﬃcient to establish which agent oﬀers the
greatest and most consistent therapeutic beneﬁt. Inﬂiximab
has been increasingly used to treat refractory uveitis and at
least one report has suggested favourability over etanercept
[8]. In-depth proﬁling of the targets and pathways of action
of these agents would help to determine their future roles
intreatinglocalizedmanifestationsofsystemicinﬂammatory
disease.
This case demonstrates that inﬂiximab can eﬀectively
stabilize active corneal rheumatoid melts resistant to con-
ventional therapy. It is unique in successfully arresting
bilateral progressive disease after multiple bilateral tectonic
keratoplasties.
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